About this trial
Cannabis Abstinence and Neurocognitive Assessment in Adolescence
Eligibility criteria
Qualifiers
Adolescents aged 15-18 years with a diagnosis of cannabis dependence or harmful cannabis use.
Disqualifiers
psychiatric comorbidity - Dual diagnosis, including psychotic disorders, mood disorders, severe organic brain damage, or autism spectrum disorder, with the exception of compensated and stabilized anxiety disorder. Psychopharmacological treatment is permitted, except for antipsychotics prescribed for psychosis.
somatic comorbidity - Severe endocrine disorders such as diabetes mellitus, thyroid dysfunction, or severe cardiovascular disease.
Violation of abstinence between the first and second neuropsychological assessments, as well as severe decompensation of mental state requiring modification of established psychopharmacological treatment.
Trial design
Treatments tested in this trial
- Neurocognitive assessment
- Urine toxicological assessment